As epithelioid trophoblastic tumor (ETT) shares similar clinical features with other gestational trophoblastic neoplasms (GTNs), it is likely to be clinically misdiagnosed and subsequently treated in an improper way. This study aimed to identify the sonographic features of ETT that are distinct from other GTNs, including placental site trophoblastic tumor (PSTT) and invasive mole/choriocarcinom...

Placental site trophoblastic tumor (PSTT) is the rare variant of gestational trophoblastic diseases (GTD), which differs histologically and immunologically from GTD. Diagnosis of PSTT is often difficult and delayed. In most cases, diagnosis is not possible until the surgery is performed. The most therapeutic choice is hysterectomy and it is usually successful. Here we report two cases of

•Gestational trophoblastic neoplasia observed distant from antecedent pregnancy•Pneumothorax is a rare presentation of intermediate trophoblastic tumors.

INTRODUCTION Gestational trophoblastic neoplasms have highly been malignant potential, which usually occurred in child-bearing age women. Unusual feature of this malignancy would be rare, it was important to take in mind the possibility of GTN in different manifestation. Based on the above mentioned, the aim of this presentation would be the management and outcome of a case series of choriocarc...

gestational trophoblastic neoplasia ( gtn) is one of the most common gynecologic tumors in our country. despite development of effective chemotherapy: some cases remain resistant and if there is only focus of tumor, resection would be indicated.we present a young woman with stage 1 persistant gtn showing no response to chemotherapy. transvaginal sonograpy revealed trophoblastic tissue in the ut...

Gestational trophoblastic neoplasia (GTN) includes invasive mole, choriocarcinoma, placental site trophoblastic tumor, and epithelioid trophoblastic tumor. The overall cure rate in treating these tumors is currently >90%. Thorough evaluation and staging allow selection of appropriate therapy that maximizes chances for cure while minimizing toxicity. Nonmetastatic (stage I) and low-risk metastat...

M. J. Seckl1, N. J. Sebire2, R. A. Fisher1, F. Golfier3, L. Massuger4 & C. Sessa5, on behalf of the ESMO Guidelines Working Group* Department of Cancer Medicine; Department of Histopathology, Charing Cross Gestational Trophoblastic Disease Centre, Charing Cross Hospital Campus of Imperial College London, London, UK; Centre de Référence des Maladie Trophoblastiques, Hospices Civils de Lyon, Lyon...